Abstract

Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer.

Original languageEnglish
Article number446
JournalCancers
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 15 2018

Fingerprint

Immunotherapy
Stem Cells
Vaccines
Antigens
Neoplasms
Proteins
Mesenchymal Stromal Cells
Biological Therapy
Natural Killer T-Cells
Colonic Neoplasms
Vascular Endothelial Growth Factor A
Immune System
Lung Neoplasms
Endothelial Cells
Public Health
Apoptosis
T-Lymphocytes
Mortality
Growth

Keywords

  • Adipose-derived stem cells
  • Antigen processing
  • Protein vaccine
  • T cell responses
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine. / Lu, Jui Hua; Peng, Bou Yue; Chang, Chun Chao; Dubey, Navneet Kumar; Lo, Wen Cheng; Cheng, Hsin Chung; Wang, Joseph R.; Wei, Hong Jian; Deng, Win Ping.

In: Cancers, Vol. 10, No. 11, 446, 15.11.2018.

Research output: Contribution to journalArticle

@article{1197937611e54a19a8942a9cc653c60d,
title = "Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine",
abstract = "Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer.",
keywords = "Adipose-derived stem cells, Antigen processing, Protein vaccine, T cell responses, Tumor microenvironment",
author = "Lu, {Jui Hua} and Peng, {Bou Yue} and Chang, {Chun Chao} and Dubey, {Navneet Kumar} and Lo, {Wen Cheng} and Cheng, {Hsin Chung} and Wang, {Joseph R.} and Wei, {Hong Jian} and Deng, {Win Ping}",
year = "2018",
month = "11",
day = "15",
doi = "10.3390/cancers10110446",
language = "English",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine

AU - Lu, Jui Hua

AU - Peng, Bou Yue

AU - Chang, Chun Chao

AU - Dubey, Navneet Kumar

AU - Lo, Wen Cheng

AU - Cheng, Hsin Chung

AU - Wang, Joseph R.

AU - Wei, Hong Jian

AU - Deng, Win Ping

PY - 2018/11/15

Y1 - 2018/11/15

N2 - Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer.

AB - Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer.

KW - Adipose-derived stem cells

KW - Antigen processing

KW - Protein vaccine

KW - T cell responses

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85057167609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057167609&partnerID=8YFLogxK

U2 - 10.3390/cancers10110446

DO - 10.3390/cancers10110446

M3 - Article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

M1 - 446

ER -